BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 6, 2024
See today's BioWorld
Home
» Progenics, Wyeth Sign MNTX Agreement Worth Up To $416M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Progenics, Wyeth Sign MNTX Agreement Worth Up To $416M
Dec. 27, 2005
By
Jennifer Boggs
No Comments
Progenics Pharmaceuticals Inc. picked up a worldwide partner for methylnaltrexone (MNTX), its investigational treatment of opioid-induced side effects, signing a deal with Wyeth Pharmaceuticals for up to $416 million. (BioWorld Today)
BioWorld